Oisín Biotechnologies is a privately held Seattle company developing genetic medicines to address age-related diseases using its Fusogenix Proteo-Lipid Vehicle (PLV) technology to deliver DNA directly to cells. Its lead programs focus on targeted fat reduction, muscle regeneration, and cellular senescence, with the fat reduction program delivering a fat‑killing genetic payload via direct injection to adipose tissue. A prior tolerability study in pigs demonstrated an excellent safety profile with no adverse effects or injection-site reactions. The company has been awarded a grant from the Methuselah Foundation to complete its first efficacy study in pigs, which will evaluate the efficacy and selectivity of two lead development candidates. The grant is described as a critical milestone in the company’s Series A workplan and support for advancing the program toward the clinic. Oisín says its technologies have attracted interest from leading pharmaceutical companies and advocacy groups, highlighting potential applicability across age-related conditions. Oisín Biotechnologies develops genetic medicines aimed at mitigating the effects of age-related diseases. The company utilizes the Fusogenix Proteo-Lipid Vehicle (PLV) delivery system developed by Entos Pharmaceuticals to deliver DNA directly to cells throughout the body. Its initial programs focus on eliminating unwanted fat cells and building muscle mass to address frailty. Oisín will use proceeds from its Series A financing to advance its pipeline toward clinical development. The company cites growing demand for therapies that address muscle loss associated with popular GLP-1 agonists. Oisín is headquartered in Seattle, Washington. Oisín Biotechnologies is a late preclinical biotechnology company focused on mitigating the effects of age-related diseases by clearing senescent cells. Its interventions are DNA-based and employ a proprietary SENSOlytics® proteo-lipid vehicle platform designed to induce apoptosis in senescent cells without harming healthy cells. In preclinical studies the company’s investigational therapeutics significantly reduced senescent cell burden in naturally aged mice and extended lifespan by more than 20%, even when treatment began in old age. The company’s most advanced program targets chronic kidney disease (CKD), with the OB-001 preclinical study readouts expected later this year. Oisín will use the new funding to advance its preclinical pipeline, progress additional indications, and move toward a regulatory filing to begin its first clinical trial. Headquartered in Seattle, the company says it will continue to explore other applications in tandem. The business completed an oversubscribed seed round raising $5 million, bringing total funding to $9.5 million.

Total raised

$20M

Funding rounds

3

Latest round

Series A

Latest activity

Jul 2024